| CAS No.: | 2023788-19-2 |
|---|---|
| Formula: | N/a |
| EINECS: | N/a |
| Type: | Peptides Powder |
| Appearance: | Powder |
| Quality: | Top Quality |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Tirzepatide |
| Appearance | White powder |
| Purity | 99% |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
| Shelf Life | 24 Months |
Description
Tirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist and is under development for the treatment
of type 2 diabetes (T2D) and obesity.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide-GLP-1 receptor agonist. Its structure is primarily
based on the glucose-dependent insulinotropic polypeptide amino acid sequence and includes a C20 fatty diacid
moiety.
Its half-life of approximately 5 days allows once-weekly subcutaneous administration. A phase 2b trial
involving patients with type 2 diabetes showed that those who received tirzepatide had dose-dependent reductions
in the glycated hemoglobin level and weight at 26 weeks.
Once-weekly injectable semaglutide, a selective GLP-1 receptor agonist, is approved for the treatment of type 2
diabetes at doses up to 1 mg. In trials involving patients who received semaglutide, the mean reductions in the
glycated hemoglobin level have been reported to be as high as 1.8 percentage points and the mean reductions in
body weight have been reported to be as high as 6.5 kg.
Application&Function
Rybelsus (semaglutide) is used together with diet and exercise to improve blood sugar control in adults with type 2
diabetes mellitus.Rybelsus is usually given after other diabetes medicines have been tried without success.
The FDA approved once-weekly semaglutide injection for chronic weight management in adults with obesity or with
overweight and at least one weight-related condition, according to an agency press release.
This is a once-weekly injectable, which is more tolerable way of managing obesity vs. other treatments. The STEP
study data showed semaglutide 2.4 mg crosses the magic threshold of 10% weight loss for many people who received it.
This is another tool that will allow clinicians to better manage obesity.
1.Helps prevent your liver from making too much sugar
2.Helps the pancreas produce more insul when your blood sugar levels are high control blood glucose
3.Can reduce hyperglycemia, especially after meals Can reduce fasting insul and fasting glucose
4.Can reduce hemoglobin A1c,Can decrease appetite and caloric intake, while inhibiting weight gain
5.Has been shown to lower triglyceride levels and oxidative stress from high LDL
6.Has been shown to help induce weight loss in obese patients with higher dosing
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}